ArticleInternational journal of obesity (2005)2026
ADRB3, LEPR, FTO and PPARG variants contribute to obesity-related metabolic syndrome in Brazilian adults: a polygenic risk score approach.
Article in International journal of obesity (2005), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePolymorphisms in genes involved in obesity-related metabolic pathways are associated with metabolic syndrome (MetS). We hypothesized that variants in FTO, LEP, LEPR, ADRB3, ADIPOQ, TCF7L2, ENPP1, APOA5, PPARG, and CYP11B2 are associated with MetS and obesity-related traits.
methodsA group of 420 subjects (179 with MetS and 241 without MetS) was selected from a Brazilian adult cohort. Clinical, anthropometric, metabolic and inflammatory data were assessed. Genetic variants were analyzed by qPCR and their association with non-genetic variables were explored using multivariate logistic and linear regression analyses. Using logistic regression results weighted by clinically relevant variants, we evaluated the prognostic capability of a polygenic risk score (PRS) model for MetS risk.
resultsADRB3 rs4994A>G (OR:3.71, 95%CI:1.71-8.03, p = 0.001) and LEPR rs1137100A>G (OR: 2.52, 95%CI: 1.33-4.79, p = 0.005) were associated with high risk of MetS. ADRB3 rs4994A>G, LEPR rs1137100A>G, FTO rs17817449T>G and PPARG rs1801282C>G predicted anthropometric, metabolic and inflammatory alterations related to MetS (p < 0.05). Normalized values of PRS (nPRS) were higher in subjects with MetS, although ROC analysis demonstrated to discriminate MetS with limited sensitivity (AUC-ROC = 0.616, p < 0.001), increasing values of nPRS were associated with higher number of MetS components (p < 0.001).
conclusionVariants in ADRB3, LEPR, FTO and PPARG play an important role in adiposity related to MetS, contributing to metabolic disturbances and pro-inflammatory state that increase cardiovascular risk in adult subjects. The integration of these variants into a polygenic risk score highlights a cumulative genetic susceptibility, as reflected by higher scores in MetS and a clear gradient across the number of MetS components.
Identifiers
42768086What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.